Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Millendo Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

Millendo Therapeutics,Inc.
Posted on: 03 Jan 18

Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases, today announced that Julia C. Owens, Ph.D., President and Chief Executive Officer, will make a formal presentation at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 11:30 AM PT. The presentation will contain a business overview and pipeline update following Millendo’s recent acquisition of Alizé Pharma SAS and subsequent expansion into Prader-Willi syndrome.

About Millendo Therapeutics, Inc.
Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome.

View source version on

Business Wire

Last updated on: 03/01/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.